The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin
Open accessAbstract
Purpose: Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1 R132MUT ) is frequent in low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed as a marker for GBMs that arise by transformation from lower-grade gliomas, regardless of clinical history. To determine how GBMs arising with IDH1 R132MUT differ from other GBMs, we undertook a comprehensive comparison of patients presenting clinically with primary GBM as a function of IDH1 R132 mutation status. Patients and Methods: In all, 618 treatment-naive primary GBMs and 235 lower-grade diffuse gliomas were sequenced for IDH1 R132 and analyzed for demographic, radiographic, anatomic, histologic, genomic, epigenetic, and transcriptional characteristics. Results: Investigation revealed a constellation of features that distinguishes IDH1 R132MUT GBMs from other GBMs (including frontal location and lesser extent of contrast enhancement and necrosis), relates them to lower-grade IDH1 R132MUT gliomas, and supports the concept that IDH1 R132MUT gliomas arise from a neural precursor population that is spatially and temporally restricted in the brain. The observed patterns of DNA sequence, methylation, and copy number alterations support a model of ordered molecular evolution of IDH1 R132MUT GBM in which the appearance of mutant IDH1 protein is an initial event, followed by production of p53 mutant protein, and finally by copy number alterations of PTEN and EGFR. Conclusion: Although histologically similar, GBMs arising with and without IDH1 R132MUT appear to represent distinct disease entities that arise from separate cell types of origin as the result of largely nonoverlapping sets of molecular events. Optimal clinical management should account for the distinction between these GBM disease subtypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Self-citationMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“that evolve from lower-grade glioma.(11-16) Herein, we sought to develop a detailed portrait of untreated GBMs arising with IDH1 with the aim of gaining insights into the manner in which IDH1 gliomas develop and to determine whether IDH1 GBM is a distinct disease entity.”
BackgroundIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Self-citationXu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Self-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Genetic Pathways to Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070011 · Cited by 1,497
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Hartmann, C., Meyer, J., Balss, J., Capper, D., Mueller, W., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027 · cited 1×
“that evolve from lower-grade glioma.(11-16) Herein, we sought to develop a detailed portrait of untreated GBMs arising with IDH1 with the aim of gaining insights into the manner in which IDH1 gliomas develop and to determine whether IDH1 GBM is a distinct disease entity.”
BackgroundIsocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaih, A., Laffaire, J., Ducray, F., El Hallani, S., Boisselier, B., Mokhtari, K., Hoang-Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,008
Origin of oligodendrocytes in the subventricular zone of the adult brain
Menn, B., Garcia-Verdugo, J. M., Yaschine, C., Gonzalez-Perez, O., Rowitch, D., & Alvarez-Buylla, A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1299-06.2006 · Cited by 972
The CpG dinucleotide and human genetic disease
Cooper, D. N., & Youssoufian, H. (1988) · Human Genetics · doi:10.1007/bf00278187 · Cited by 931
Barnea-Goraly, N., Menon, V., Eckert, M., Tamm, L., Bammer, R., Karchemskiy, A., Dant, C. C., & Reiss, A. L. (2005) · Cerebral Cortex · doi:10.1093/cercor/bhi062 · Cited by 848
Subtypes of medulloblastoma have distinct developmental origins
Gibson, P., Tong, Y., Robinson, G., Thompson, M. C., Currle, D. S., Eden, C., Kranenburg, T. A., Hogg, T., Poppleton, H., Martin, J., et al. (2010) · Nature · doi:10.1038/nature09587 · Cited by 831
Radial glia cells are candidate stem cells of ependymoma
Taylor, M. D., Poppleton, H., Fuller, C., Su, X., Liu, Y., Jensen, P., Magdaleno, S., Dalton, J., Calabrese, C., Board, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.001 · Cited by 829
Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00848.x · Cited by 740
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Nobusawa, S., Watanabe, T., Kleihues, P., & Ohgaki, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0715 · Cited by 711
Alcantara Llaguno, S., Chen, J., Kwon, C.-H., Jackson, E. L., Li, Y., Burns, D. K., Alvarez-Buylla, A., & Parada, L. F. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.006 · Cited by 694
Paugh, B. S., Qu, C., Jones, C., Liu, Z., Adamowicz-Brice, M., Zhang, J., Bax, D. A., Coyle, B., Barrow, J., Hargrave, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7252 · Cited by 654
Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., Westphal, M., Schackert, G., Simon, M., Tonn, J. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0805 · Cited by 614
Self-citationIDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Ichimura, K., Pearson, D. M., Kocialkowski, S., Bäcklund, L. M., Chan, R., Jones, D. T. W., & Collins, V. P. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-025 · Cited by 595
A Hierarchy of Self-Renewing Tumor-Initiating Cell Types in Glioblastoma
Chen, R., Nishimura, M. C., Bumbaca, S. M., Kharbanda, S., Forrest, W. F., Kasman, I. M., Greve, J. M., Soriano, R. H., Gilmour, L. L., Rivers, C. S., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.049 · Cited by 544
Self-citationJackson, E. L., Garcia-Verdugo, J. M., Gil-Perotin, S., Roy, M., Quinones-Hinojosa, A., VandenBerg, S., & Alvarez-Buylla, A. (2006) · Neuron · doi:10.1016/j.neuron.2006.06.012 · Cited by 542
Günther, H. S., Schmidt, N. O., Phillips, H. S., Kemming, D., Kharbanda, S., Soriano, R., Modrusan, Z., Meissner, H., Westphal, M., & Lamszus, K. (2008) · Oncogene · doi:10.1038/sj.onc.1210949 · Cited by 443
Self-citationMR imaging correlates of survival in patients with high-grade gliomas.
Pope, W. B., Sayre, J. W., Perlina, A., Villablanca, J. P., Mischel, P. S., & Cloughesy, T. F. (2005) · PubMed Central · Cited by 418
Self-citationCross-species genomics matches driver mutations and cell compartments to model ependymoma
Johnson, R. A., Wright, K. D., Poppleton, H., Mohankumar, K. M., Finkelstein, D., Pounds, S. B., Rand, V., Leary, S. E. S., White, E., Eden, C., et al. (2010) · Nature · doi:10.1038/nature09173 · Cited by 367
Genetic alterations and signaling pathways in the evolution of gliomas
Ohgaki, H., & Kleihues, P. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01308.x · Cited by 355
A functional role for EGFR signaling in myelination and remyelination
Aguirre, A., Dupree, J. L., Mangin, J. M., & Gallo, V. (2007) · Nature Neuroscience · doi:10.1038/nn1938 · Cited by 352
Regulatory networks define phenotypic classes of human stem cell lines
Müller, F.-J., Laurent, L. C., Kostka, D., Ulitsky, I., Williams, R., Lu, C., Park, I.-H., Rao, M. S., Shamir, R., Schwartz, P. H., et al. (2008) · Nature · doi:10.1038/nature07213 · Cited by 343
Self-citationSubsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis
von Deimling, A., von Ammon, K., Schoenfeld, D., Wiestler, O. D., Seizinger, B. R., & Louis, D. N. (1993) · Brain Pathology · doi:10.1111/j.1750-3639.1993.tb00721.x · Cited by 331
Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms
Green, A., & Beer, P. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0910063 · Cited by 285
Recent Advances in Therapy for Glioblastoma
Clarke, J., Butowski, N., & Chang, S. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.5 · Cited by 283
Schiffman, J. D., Hodgson, J. G., VandenBerg, S. R., Flaherty, P., Polley, M.-Y. C., Yu, M., Fisher, P. G., Rowitch, D. H., Ford, J. M., Berger, M. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1851 · Cited by 251
Self-citationNon-Stem Cell Origin for Oligodendroglioma
Persson, A. I., Petritsch, C., Swartling, F. J., Itsara, M., Sim, F. J., Auvergne, R., Goldenberg, D. D., Vandenberg, S. R., Nguyen, K. N., Yakovenko, S., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.033 · Cited by 242
Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.
Ƶlatescu, M. C., TehraniYazdi, A., Sasaki, H., Megyesi, J. F., Betensky, R. A., Louis, D. N., & Cairncross, J. G. (2001) · PubMed · Cited by 235
Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma
Lindberg, N., Kastemar, M., Olofsson, T., Smits, A., & Uhrbom, L. (2009) · Oncogene · doi:10.1038/onc.2009.76 · Cited by 212
Single-cell gene profiling defines differential progenitor subclasses in mammalian neurogenesis
Kawaguchi, A., Ikawa, T., Kasukawa, T., Ueda, H. R., Kurimoto, K., Saitou, M., & Matsuzaki, F. (2008) · Development · doi:10.1242/dev.022616 · Cited by 193
Mutant Metabolic Enzymes Are at the Origin of Gliomas
Yan, H., Bigner, D. D., Velculescu, V. E., & Parsons, D. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2650 · Cited by 171
IDH1andIDH2Mutations in Gliomas
Carli, E. D., Wang, X.-W., & Puget, S. (2009) · New England Journal of Medicine · doi:10.1056/nejmc090593 · Cited by 142
Fujisawa, H., Kurrer, M. O., Reis, R. M., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65135-8 · Cited by 130
Harris, L. W., Lockstone, H. E., Khaitovich, P., Weickert, C. S., Webster, M. J., & Bahn, S. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-28 · Cited by 121
Glioma Formation, Cancer Stem Cells, and Akt Signaling
Hambardzumyan, D., Squatrito, M., Carbajal, E., & Holland, E. C. (2008) · Stem Cell Reviews and Reports · doi:10.1007/s12015-008-9021-5 · Cited by 100
Signaling in Malignant Astrocytomas: Role of Neural Stem Cells and Its Therapeutic Implications
Llaguno, S. R. A., Chen, J., & Parada, L. F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0433 · Cited by 40
Rodin, S. N., & Rodin, A. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11927 · Cited by 34
(1999) · doi:10.1002/(sici)1097-4547(19990815)57:4<435::aid-jnr3>3.0.co;2-l
Cited by
Epidemiologic and Molecular Prognostic Review of Glioblastoma
Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0275 · Cited by 1,390
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Alexander, B. M., & Cloughesy, T. F. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0119 · Cited by 788
Self-citationGenetic and molecular epidemiology of adult diffuse glioma
Molinaro, A. M., Taylor, J. W., Wiencke, J. K., & Wrensch, M. R. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0220-2 · Cited by 709
Metadata
- Authors
- Lai, A., Kharbanda, S., Pope, W. B., Tran, A., Solis, O. E., Peale, F., Forrest, W. F., Pujara, K., Carrillo, J. A., Pandita, A., Ellingson, B. M., Bowers, C. W., Soriano, R. H., Schmidt, N. O., Mohan, S., Yong, W. H., Seshagiri, S., Modrusan, Z., Jiang, Z., Aldape, K. D., Mischel, P. S., Liau, L. M., Escovedo, C. J., Chen, W., Nghiemphu, P. L., James, C. D., Prados, M. D., Westphal, M., Lamszus, K., Cloughesy, T., & Phillips, H. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-12-01
- Volume
- 29
- Issue
- 34
- Pages
- 4482-4490
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2100795816
- Cited by
- 433
- References
- 54
- FWCI
- 15.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.